EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)

Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer

Caicun Zhou, Chongyang Li, Libo Luo, Xin Li, Keyi Jia, Ning He, Shiqi Mao, Wanying Wang, Chuchu Shao, Xinyu Liu, Kan Huang, Yaxin Yu und 17 weitere

Cancer Cell · 2024-07 · 42 (7) · 1286-1300.e8

DOI: 10.1016/j.ccell.2024.06.001 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Cancer Cell, 2024-07. Verfasst von Caicun Zhou und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China. Electronic address: caicu…. Hauptthemen laut MEDLINE: Proteasome Inhibitors, Proto-Oncogene Proteins p21(ras), Mutation. Die Arbeit wurde bisher 115-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: National Key Clinical Specialty Discipline Construction Program of China, Shanghai Shenkang Hospital Development Center, Science and Technology Commission of Shanghai Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

KRAS G12D is the most frequently mutated oncogenic KRAS subtype in solid tumors and remains undruggable in clinical settings. Here, we developed a high affinity, selective, long-acting, and non-covalent KRAS G12D inhibitor, HRS-4642, with an affinity constant of 0.083 nM. HRS-4642 demonstrated robust efficacy against KRAS G12D-mutant cancers both in vitro and in vivo. Importantly, in a phase 1 clinical trial, HRS-4642 exhibited promising anti-tumor activity in the escalating dosing cohorts. Furthermore, the sensitization and resistance spectrum for HRS-4642 was deciphered through genome-wide CRISPR-Cas9 screening, which unveiled proteasome as a sensitization target. We further observed that the proteasome inhibitor, carfilzomib, improved the anti-tumor efficacy of HRS-4642. Additionally, HRS-4642, either as a single agent or in combination with carfilzomib, reshaped the tumor microenvironment toward an immune-permissive one. In summary, this study provides potential therapies for patients with KRAS G12D-mutant cancers, for whom effective treatments are currently lacking.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proteasome InhibitorsProto-Oncogene Proteins p21(ras)MutationHumansMiceAnimalsXenograft Model Antitumor AssaysOligopeptidesCell Line, TumorFemaleNeoplasmsTumor MicroenvironmentAntineoplastic Combined Chemotherapy ProtocolsProteasome Endopeptidase ComplexMice, Nude

Stichwörter der Autor:innen

HRS-4642KRAS G12Dcarfilzomibtumor immune microenvironment

Substanzen

Proteasome InhibitorsProto-Oncogene Proteins p21(ras)KRAS protein, humancarfilzomibOligopeptidesProteasome Endopeptidase Complex

Autor:innen und Institutionen

  • Department of Medical Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China. Electronic address: caicunzhou_dr@163.com.
  • Department of Medical Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China; Department of Pathology and Frontier Innovation Center, School of Basic Medical Sciences, Fudan…
  • Department of Medical Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China.
  • Shanghai Hengrui Pharmaceutical Co., LTD, Shanghai 200433, China.
  • Department of Pathology and Frontier Innovation Center, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China; Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai 20003…
  • Department of Pathology and Frontier Innovation Center, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.

Förderung

  • National Key Clinical Specialty Discipline Construction Program of China
  • Shanghai Shenkang Hospital Development Center
  • Science and Technology Commission of Shanghai Municipality
  • Program for Professor of Special Appointment Eastern Scholar at Shanghai Institutions of Higher Learning
  • National Key Research and Development Program of China
  • Shanghai Rising-Star Program
  • National Natural Science Foundation of China

Zitieren

APA

Zhou, C., Li, C., Luo, L., Li, X., Jia, K., He, N., Mao, S., Wang, W., Shao, C., Liu, X., Huang, K., Yu, Y., Cai, X., Chen, Y., Dai, Z., Li, W., Yu, J., Li, J., Shen, F., …, & Ren, S. (2024). Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer. Cancer Cell, 42(7), 1286-1300.e8. https://doi.org/10.1016/j.ccell.2024.06.001

Vancouver

Zhou C, Li C, Luo L, Li X, Jia K, He N, et al. Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer. Cancer Cell. 2024;42(7):1286-1300.e8. doi:10.1016/j.ccell.2024.06.001

BibTeX
@article{Zhou2024,
  author = {Zhou, Caicun and Li, Chongyang and Luo, Libo and Li, Xin and Jia, Keyi and He, Ning and Mao, Shiqi and Wang, Wanying and Shao, Chuchu and Liu, Xinyu and Huang, Kan and Yu, Yaxin and Cai, Xinlei and Chen, Yingxue and Dai, Zican and Li, Wei and Yu, Jia and Li, Jiayu and Shen, Feng and Wang, Zaiyong and He, Feng and Sun, Xing and Mao, Rongfu and Shi, Wei and Zhang, Jun and Jiang, Tao and Zhang, Zhe and Li, Fei and Ren, Shengxiang},
  title = {Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer},
  journal = {Cancer Cell},
  year = {2024},
  volume = {42},
  number = {7},
  pages = {1286--1300.e8},
  doi = {10.1016/j.ccell.2024.06.001}
}
Kostenlos starten →